People living with amyotrophic lateral sclerosis (ALS) may benefit from the addition of two medications to the Saskatchewan Drug Plan.
The province is listing Albrioza (sodium phenylbutyrate and ursodoxicoltaurine) and the oral suspension of Radicava (edaravone) on the Saskatchewan Drug Plan Formulary.
From Sep. 1, eligible ALS patients who meet certain medical criteria may be considered for coverage of these medications by the provincial plan.
ALS is a fatal neurodegenerative disease that affects around 3,000 Canadians. ALS rapidly causes patients to lose the ability to move and speak.
Patients and families who think they or their family member may benefit are encouraged to speak with their physician.
